Search results
Results from the WOW.Com Content Network
Congenital varicella syndrome is a rare disease resulting from Varicella Zoster virus (VZV) infection during the period of gestation. Viremia during the primary infection can result in transplacental transmission of the infection to the developing fetus .
Varicella is a particular problem in hospitals when there are patients with immune systems weakened by drugs (e.g., high-dose steroids) or HIV. [ 75 ] Secondary bacterial infection of skin lesions, manifesting as impetigo , cellulitis , and erysipelas , is the most common complication in healthy children.
TORCH syndrome is a cluster of symptoms caused by congenital infection with toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and other organisms including syphilis, parvovirus, and Varicella zoster. [1] Zika virus is considered the most recent member of TORCH infections. [2]
Since the discovery in the mid-1970s, it has been used as an effective drug for the treatment of infections caused by most known species of the herpesvirus family, including herpes simplex and varicella zoster viruses. Nucleosides isolated from a Caribbean sponge, Cryptotethya crypta, were the basis for the synthesis of aciclovir.
The varicella vaccine is not recommended for seriously ill people, pregnant women, people who have tuberculosis, people who have experienced a serious allergic reaction to the varicella vaccine in the past, people who are allergic to gelatin, people allergic to neomycin, people receiving high doses of steroids, people receiving treatment for ...
In the last decades, triazolopyrimidines and their metal complexes have been looked at as an alternative drug to the existing commercial antimonials, searching for a decrease in side effects and the development of parasite drug resistance. [13]
"I think I was only there the first day. Maybe I made it to day two," she added. "We did the read-throughs and they staged it, and then they're like, we better get somebody else."
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). [10] [11] It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor [6] that is designed to bind to the fusion protein on the surface of the RSV virus.